journal article·2025-11Open access

Advances and challenges of targeted protein degradation in ophthalmology: Future directions and therapeutic potential

Ke Feng, Mingyan Wei, Panqin Ma, Jiaoyue Hu, Caihong Huang, Yi Han, Zuguo Liu

Materials & Design· Volume 259

Abstract

The advent of targeted protein degradation technologies, particularly proteolysis-targeting chimeras (PROTACs) and lysosome-targeting chimeras (LYTACs), is poised to revolutionize therapeutic strategies in ophthalmology. This review presents the first systematic analysis of these protein degradation platforms to address ’undruggable’ targets in ocular pathologies. Harnessing distinct cellular machinery through the engagement of the ubiquitin–proteasome system and the lysosomal pathway with PROTACs and LYTACs, respectively, these heterobifunctional molecules enable the targeted elimination of disease-driving proteins implicated in ocular surface diseases, such as dry eye, and fundus diseases, including age-related macular degeneration, diabetic retinopathy, and glaucoma. We review the mechanistic basis of these technologies, their translational potential in overcoming the limitations of conventional therapies, and ocular-specific challenges such as optimizing bioavailability and intraocular target selectivity. Central to this discussion is the role of advanced linker engineering in achieving spatio-temporal control of degradation activity. While barriers to ocular biodistribution and sustained delivery remain, targeted protein degradation represents a paradigm shift in ophthalmology, offering durable therapeutic effects that could significantly improve clinical outcomes and patient compliance through reduced dosing frequency.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Protein Degradation and Inhibitors · Ubiquitin and proteasome pathways · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Global Journal for Research Analysis.
2. A, S. E., Moses, P. D., George, R., Indian Pediatr 2005, 42, 942.10.4103/0019-509X.16701 ↗
3. Abelson · Expert Opin. Pharmacother. · 2015 · 16 · 121910.1517/14656566.2015.1040760 ↗
4. Agarwal · Drug Discov. Today · 2016 · 21 · 97710.1016/j.drudis.2016.04.002 ↗
5. Agostini, H., Abreu, F., Baumal, C. R., Chang, D. S., K, G. C., Demetriades, A. M., Kodjikian, L., Lim, J. I., Margaron, P., Mones, J. M., Peto, T., Ricci, F., Ruth, M., Singh, R. P., Stoilov, I., Swaminathan, B., Willis, J. R., Westenskow, P. D., Graefes Arch Clin Exp Ophthalmol 2024, 262, 3437.10.1007/s00417-024-06531-9 ↗
6. Ahn · Cell Chem. Biol. · 2021 · 28 · 107210.1016/j.chembiol.2021.02.024 ↗
7. Ahn · Nat. Chem. Biol. · 2021 · 17 · 93710.1038/s41589-021-00770-1 ↗
8. Akiyode · J. Pharm. Technol. · 2016 · 32 · 2210.1177/8755122515599552 ↗
9. Alabi · J. Biol. Chem. · 2021 · 29610.1016/j.jbc.2021.100647 ↗
10. Alkatan · 2019
11. Alkholief, M., Kalam, M. A., Alshememry, A. K., Ali, R., Alhudaithi, S. S., Alsaleh, N. B., Raish, M., Alshamsan, A., Nanomaterials (Basel) 2023, 13.10.3390/nano13040681 ↗
12. Allard-Chamard · Blood Adv. · 2025 · 9 · 52010.1182/bloodadvances.2024013267 ↗
13. Allocca · Oncotarget · 2017 · 8 · 6870710.18632/oncotarget.19844 ↗
14. Ang, B. C. H., Lim, S. Y., Betzler, B. K., Wong, H. J., Stewart, M. W., Dorairaj, S., Bioengineering (Basel) 2023, 10.10.3390/bioengineering10091096 ↗
15. Atallah · Clin. Ophthalmol. · 2019 · 13 · 103310.2147/OPTH.S191635 ↗
16. Athanasiou · Prog. Retin. Eye Res. · 2018 · 62 · 110.1016/j.preteyeres.2017.10.002 ↗
17. Awwad · Oncoimmunology · 2018 · 710.1080/2162402X.2018.1486356 ↗
18. Baba · Cell. Physiol. Biochem. · 2015 · 35 · 38610.1159/000369704 ↗
19. Bajwa · Future Healthc J · 2021 · 8 · e18810.7861/fhj.2021-0095 ↗
20. Balan · 2023 · 7
21. Balch · Science · 2008 · 319 · 91610.1126/science.1141448 ↗
22. Banik · Nature · 2020 · 584 · 29110.1038/s41586-020-2545-9 ↗
23. Barnett · Gerontology · 2013 · 59 · 29710.1159/000346169 ↗
24. Bekes · Nat. Rev. Drug Discov. · 2022 · 21 · 18110.1038/s41573-021-00371-6 ↗
25. Benitez-Del-Castillo · Invest. Ophthalmol. Vis. Sci. · 2016 · 57 · 644710.1167/iovs.16-20303 ↗
26. Benowitz · Expert Opin. Ther. Pat. · 2021 · 31 · 110.1080/13543776.2021.1840553 ↗
27. Billaud · Pharmacol. Rev. · 2014 · 66 · 51310.1124/pr.112.007351 ↗
28. Bond · RSC Chem. Biol. · 2021 · 2 · 72510.1039/D1CB00011J ↗
29. Bucolo · Front. Pharmacol. · 2012 · 3
30. Budnar · Biochemistry (Mosc.) · 2022 · 87 · 22510.1134/S000629792203004X ↗
31. Buhimschi · Biochemistry · 2018 · 57 · 356410.1021/acs.biochem.8b00391 ↗
32. Burgoyne · Exp. Eye Res. · 2011 · 93 · 12010.1016/j.exer.2010.09.005 ↗
33. Burslem · Cell · 2020 · 181 · 10210.1016/j.cell.2019.11.031 ↗
34. Burslem · Cell Chem. Biol. · 2018 · 25 · 6710.1016/j.chembiol.2017.09.009 ↗
35. Byl · ACS Infect. Dis. · 2023 · 9 · 70610.1021/acsinfecdis.3c00012 ↗
36. Camberlein · 2022 · 11
37. Campa · Curr. Drug Targets · 2016 · 17 · 32810.2174/1573399811666150615151324 ↗
38. Cantley · Nat. Commun. · 2022 · 13 · 681410.1038/s41467-022-34562-5 ↗
39. Cao · Br. J. Ophthalmol. · 2016 · 100 · 71310.1136/bjophthalmol-2015-307213 ↗
40. Cetin · Biomolecules · 2021 · 1110.3390/biom11010060 ↗
41. Chamberlain · Nat. Chem. Biol. · 2019 · 15 · 93710.1038/s41589-019-0362-y ↗
42. Chan · J. Pharm. Pharm. Sci. · 2019 · 22 · 4910.18433/jpps29895 ↗
43. Chan · Sci. Transl. Med. · 2021 · 1310.1126/scitranslmed.abd3438 ↗
44. Charani · Indian Journal of Clinical and Experimental Ophthalmology · 2021 · 7 · 8310.18231/j.ijceo.2021.017 ↗
45. Chen · J. Neuroinflammation · 2022 · 19 · 18310.1186/s12974-022-02547-2 ↗
46. Chen · J. Clin. Invest. · 2025
47. Chen · Cancers (Basel) · 2024 · 16
48. Chen · Biochem. Biophys. Res. Commun. · 2018 · 506 · 86810.1016/j.bbrc.2018.10.175 ↗
49. Chen · Lab. Invest. · 2012 · 92 · 55610.1038/labinvest.2011.189 ↗
50. Choi · J. Biol. Chem. · 2010 · 285 · 3211610.1074/jbc.M110.131284 ↗
51. Churcher · J. Med. Chem. · 2018 · 61 · 44410.1021/acs.jmedchem.7b01272 ↗
52. Cildag · Postepy Dermatol Alergol · 2018 · 35 · 51610.5114/ada.2017.71422 ↗
53. Clerin · Cold Spring Harb. Perspect. Med. · 2024 · 1410.1101/cshperspect.a041284 ↗
54. Cordero · EMBO J. · 2014 · 33 · 1474
55. Crawford · J Cell Commun Signal · 2011 · 5 · 10110.1007/s12079-011-0121-7 ↗
56. Cunha · J. Bras. Pneumol. · 2018 · 44 · 43910.1590/s1806-37562017000000325 ↗
57. Das · Indian J. Ophthalmol. · 2016 · 64 · 410.4103/0301-4738.178154 ↗
58. Dascalu · 2024 · 14
59. de Jong · Prog. Retin. Eye Res. · 2021 · 8410.1016/j.preteyeres.2021.100952 ↗
60. De Luisi · Clin. Cancer Res. · 1935 · 2011 · 17
61. de Paula · J. Mol. Histol. · 2017 · 48 · 32910.1007/s10735-017-9731-6 ↗
62. Di · J. Biol. Chem. · 2015 · 290 · 1252310.1074/jbc.M115.642637 ↗
63. Ding · Chem. Eng. J. · 2024 · 499
64. Ding · Trends Pharmacol. Sci. · 2020 · 41 · 46410.1016/j.tips.2020.04.005 ↗
65. Ding · Chem. Soc. Rev. · 2022 · 51 · 883210.1039/D2CS00624C ↗
66. Dixon · Curr. Opin. Chem. Biol. · 2009 · 13 · 54910.1016/j.cbpa.2009.08.003 ↗
67. Dong · Biochem. Biophys. Res. Commun. · 2015 · 465 · 67810.1016/j.bbrc.2015.08.014 ↗
68. Doucette · Ophthalmic Genet. · 2017 · 38 · 10810.3109/13816810.2016.1164193 ↗
69. Dreicer · Curr. Oncol. Rep. · 2007 · 9 · 12010.1007/s11912-007-0008-1 ↗
70. Duarte · Ophthalmic Plast. Reconstr. Surg. · 2024 · 40 · 36710.1097/IOP.0000000000002573 ↗
71. Dutta Majumder · Ocul. Immunol. Inflamm. · 2024 · 32 · 209210.1080/09273948.2024.2323671 ↗
72. Enoki · Biochim. Biophys. Acta · 2010 · 1802 · 74910.1016/j.bbadis.2010.06.001 ↗
73. Erika Paige, H., Linda, T. V., Hyo, S. H., Jennifer, R., Richard, G., Chi Fung Anther, K., Deborah, C., Sara Alsterlind, H., Cancer Research 2022.
74. Falcão · 2025 · 14
75. Fang · Chem. Sci. · 2024
76. Farnaby · Nat. Chem. Biol. · 2019 · 15 · 67210.1038/s41589-019-0294-6 ↗
77. Farne · Thorax · 2022 · 77 · 95010.1136/thoraxjnl-2021-217429 ↗
78. Feng · Biomark Res · 2024 · 12 · 8510.1186/s40364-024-00638-1 ↗
79. Feng · Life · 2022 · 12 · 15710.3390/life12020157 ↗
80. Fernandez-Albarral · Front. Cell. Neurosci. · 2024 · 1810.3389/fncel.2024.1354569 ↗
81. Finley · Annu. Rev. Biochem · 2009 · 78 · 47710.1146/annurev.biochem.78.081507.101607 ↗
82. Fitch · J. Cell Biol. · 1990 · 110 · 145710.1083/jcb.110.4.1457 ↗
83. Floyd · PLoS One · 2012 · 710.1371/journal.pone.0050704 ↗
84. Furue · Clin. Med. · 2021 · 10
85. Gadzinski · Beilstein J. Nanotechnol. · 2022 · 13 · 116710.3762/bjnano.13.98 ↗
86. Gant · J. Neurosci. · 2018 · 38 · 103010.1523/JNEUROSCI.2234-17.2017 ↗
87. Gao · ACS Med. Chem. Lett. · 2020 · 11 · 23710.1021/acsmedchemlett.9b00597 ↗
88. García Jiménez · J. Med. Chem. · 2022 · 65 · 1263910.1021/acs.jmedchem.2c00201 ↗
89. Gehrke · Cells · 2022 · 1110.3390/cells11121881 ↗
90. Gemenetzi · Eye (Lond.) · 2017 · 31 · 110.1038/eye.2016.208 ↗
91. Gerhardt · 2022 · 11
92. Gigante · J. Neurol. Neurosurg. Psychiatry · 2011 · 82 · 24710.1136/jnnp.2010.211144 ↗
93. Goldberg · Nature · 2003 · 426 · 89510.1038/nature02263 ↗
94. Gorbatyuk · PNAS · 2010 · 107 · 596110.1073/pnas.0911991107 ↗
95. Gou · Front Biosci (landmark Ed) · 2024 · 29 · 17510.31083/j.fbl2905175 ↗
96. Griciuc · PLoS Genet. · 2010 · 610.1371/journal.pgen.1001075 ↗
97. Grossman · 2023 · 16
98. Gu · Bioessays · 2018 · 4010.1002/bies.201700247 ↗
99. Gu · Ophthalmol Ther · 2022 · 11 · 11310.1007/s40123-021-00408-4 ↗
100. Haber · Ther Adv Ophthalmol · 2019 · 11